info@birdgroup.be

Login

Papers

Inflamm Bowel Dis. 2018 Jun 15. doi: 10.1093/ibd/izy219. [Epub ahead of print]
Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort.

Acta Gastroenterol Belg. 2018 Jan-Mar;81(1):49-53.
Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD)

United European Gastroenterology Journal, First Published 20 Jun 2018.
Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice

United European Gastroenterol J. 2018 Apr;6(3):439-445
Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists

Inflamm Bowel Dis - Volume 19, Number 10, September 2013
Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy

Journal of Crohn's and Colitis (2013) 7, 154-160
Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn\'s patients

Journal of Crohn's and Colitis (2013) 7, e588-e598
Profile of pediatric Crohn's disease in Belgium

Journal of Crohn's and Colitis (2012) 6, 557-562
Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naÃ¯ve patients with ulcerative colitis

‹
1
2
3
4
5
6
7
›